Insider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Sells $1,084,600.00 in Stock

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Badreddin Edris sold 20,000 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total value of $1,084,600.00. Following the transaction, the chief operating officer now directly owns 169,712 shares in the company, valued at approximately $9,203,481.76. This represents a 10.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Badreddin Edris also recently made the following trade(s):

• On Monday, February 10th, Badreddin Edris sold 30,000 shares of SpringWorks Therapeutics stock. The stock was sold at an average price of $53.13, for a total value of $1,593,900.00.

SpringWorks Therapeutics Stock Down 3.4 %

SWTX opened at $49.55 on Friday. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00. The company has a fifty day simple moving average of $44.41 and a 200 day simple moving average of $38.84. The stock has a market cap of $3.71 billion, a P/E ratio of -14.24 and a beta of 0.76.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The firm had revenue of $61.55 million during the quarter, compared to the consensus estimate of $60.53 million. On average, equities research analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on SWTX. Evercore ISI upped their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Guggenheim dropped their target price on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a research report on Friday, February 21st. Finally, Wedbush reiterated an “outperform” rating and set a $81.00 target price on shares of SpringWorks Therapeutics in a research report on Thursday, February 20th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $73.20.

Institutional Trading of SpringWorks Therapeutics

Large investors have recently made changes to their positions in the company. Huntington National Bank increased its holdings in SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after purchasing an additional 192 shares in the last quarter. AlphaQuest LLC increased its holdings in SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after purchasing an additional 414 shares in the last quarter. Venturi Wealth Management LLC bought a new position in SpringWorks Therapeutics during the 4th quarter worth about $45,000. State of Wyoming increased its holdings in SpringWorks Therapeutics by 39.5% during the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock worth $55,000 after purchasing an additional 433 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in SpringWorks Therapeutics during the 4th quarter worth about $56,000.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.